今天克罗恩病和临床管理:它是如何发生的?
Ronaldo Teixeira da Silva Júnior1, Jonathan Santos Apolonio1, Jessica Oliveira de Souza Nascimento1
1Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil.
World journal of methodology
|January 17, 2024
概括
克罗恩氏病 (CD) 是一种由免疫介导的炎症性肠病,由遗传,环境和微生物因素造成. 目前的管理包括诊断,缓解诱导/维持用抗炎药物,手术和非药物干预的缓解.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 内部医学 内部医学
背景情况:
- 克罗恩病 (CD) 是一种免疫媒介的炎症性肠病 (IBD).
- 病因学涉及遗传,环境和微生物相互作用.
- 病理生理学包括升高的互白蛋白 (IL-12,IL-17),Th1概况和耐受性丧失.
研究的目的:
- 审查克罗恩病临床管理中的当前证据.
- 讨论CD的病理生理学,监测和相关疾病.
主要方法:
- 审查目前CD的临床管理策略.
- 讨论诊断工具,如便calprotectin,胆结肠镜和囊内镜.
- 治疗选择的概述,包括抗炎药物,手术和非药物干预.
主要成果:
- CD管理的目的是诱导和维持缓解.
- 治疗方案包括皮质类固醇,免疫调节剂,生物药物,手术和非药物方法.
- 相关疾病包括肌肉骨,皮肤,眼睛,肝脏和血液学变化.
结论:
- 目前的证据支持对CD管理采取多方面的方法.
- 了解病理生理学和相关疾病对于综合护理至关重要.
- 综合治疗策略对于改善克罗恩病患者的治疗结果至关重要.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Inflammatory Bowel Disease V: Surgical Management
147
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
147
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
139
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139


